NCT02447419 2022-06-15
Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors
Samsung Medical Center
Phase 2 Completed
Samsung Medical Center
St. Jude Children's Research Hospital
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center